✓ Translated by DotMD AI Clinical Council Source: Clinical genitourinary cancer • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37263910 ↗

Phase III Randomized Trial: Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial (N = 328)

Original Paper Title: “Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 328
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.
  • Study Design & Sample: Phase III Randomized Trial published in Clinical genitourinary cancer (N = 328 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical genitourinary cancer (2023), this phase iii randomized trial evaluating 328 human participants investigated: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. Key clinical takeaway: Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical genitourinary cancer, 2023-10-15; N = 328; Rigor 87/100): Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: complete-dual-action-famotidine-calcium-carbonate-and-magnesium → Rx: docetaxel → Condition: prostate-cancer → Condition: jaw-injuries-and-disorders → Condition: kidney-cancer →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37263910: Phase III Randomized Trial: Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial (N = 328)

3 of 3 Free Questions Remaining